1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Acne And Related Disorders – Pipeline Review, H1 2013

Acne And Related Disorders – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 167 pages

Acne And Related Disorders – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Acne And Related Disorders - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Acne And Related Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acne And Related Disorders. Acne And Related Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Acne And Related Disorders.
- A review of the Acne And Related Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Acne And Related Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Acne And Related Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Acne And Related Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Acne And Related Disorders - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Acne And Related Disorders Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Acne And Related Disorders 10
Acne And Related Disorders Therapeutics under Development by Companies 12
Acne And Related Disorders Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Discovery and Pre-Clinical Stage Products 21
Comparative Analysis 21
Acne And Related Disorders Therapeutics - Products under Development by Companies 22
Acne And Related Disorders Therapeutics - Products under Investigation by Universities/Institutes 26
Companies Involved in Acne And Related Disorders Therapeutics Development 27
Boehringer Ingelheim GmbH 27
Photocure ASA 28
Valeant Pharmaceuticals International 29
GlaxoSmithKline plc 30
Galderma S.A. 31
Meda AB 32
Merz GmbH and Co. KGaA 33
Toyama Chemical Co. Ltd 34
Paratek Pharmaceuticals, Inc. 35
AntiCancer, Inc. 36
Helix BioMedix, Inc. 37
Cosmo Pharmaceuticals S.p.A 38
XOMA Ltd. 39
Quest PharmaTech Inc. 40
Phynova Group Ltd 41
Syntopix Group Plc 42
Phosphagenics Limited 43
Foamix Ltd. 44
Novabiotics Ltd 45
AndroScience Corporation 46
Hygeia Therapeutics, Inc. 47
NovaLead Pharma Pvt. Ltd. 48
NanoBio Corporation 49
ELORAC, Inc. 50
Laboratorios SALVAT S.A. 51
Braintree Laboratories, Inc. 52
Maruho Co.,Ltd. 53
Lee's Pharmaceutical Holdings Limited 54
Mimetica Pty Ltd. 55
Fibrocell Sciences, Inc. 56
Ausio Pharmaceuticals, LLC 57
XBiotech USA, Inc. 58
FunZyme BioTechnologies S.A. 59
Immune Technologies and Medicine 60
Advancell 61
Acne And Related Disorders - Therapeutics Assessment 62
Assessment by Monotherapy Products 62
Assessment by Combination Products 63
Assessment by Route of Administration 64
Assessment by Molecule Type 66
Drug Profiles 68
HB-1345 - Drug Profile 68
FX-125-L - Drug Profile 69
PYN-6 - Drug Profile 71
tretinoin - Drug Profile 73
IDP-107 - Drug Profile 74
ICX-RHY - Drug Profile 75
HYG-440 - Drug Profile 77
HYG-430 - Drug Profile 79
HYG-420 - Drug Profile 80
HYG-410 - Drug Profile 81
ASCJ-9 - Drug Profile 82
azficel-T - Drug Profile 83
AUS-131 - Drug Profile 85
Visonac - Drug Profile 87
Lipo-4MA - Drug Profile 88
gevokizumab - Drug Profile 89
CB-03-01 - Drug Profile 92
NB-003 - Drug Profile 94
minocycline - Drug Profile 95
Drug For Acne - Drug Profile 96
PTK-AR-01 - Drug Profile 97
clindamycin phosphate + benzoyl peroxide - Drug Profile 98
DRM-01 - Drug Profile 99
carbamide peroxide - Drug Profile 100
BLI-1100 - Drug Profile 101
ozenoxacin - Drug Profile 102
MTC-896 - Drug Profile 104
NLP-44 - Drug Profile 106
Skin Infection Project - Drug Profile 107
clindamycin + tretinoin - Drug Profile 108
onabotulinumtoxinA - Drug Profile 109
CD2475/101 - Drug Profile 110
JNJ-10229570-AAA - Drug Profile 111
M-108101 - Drug Profile 112
SL-017 - Drug Profile 113
RA-18C3 - Drug Profile 115
(azelaic acid + citric acid + salicylic acid + ascorbic acid) - Drug Profile 117
ARK-E021 - Drug Profile 119
HO/04/09 - Drug Profile 120
FibroStem - Drug Profile 121
CD-5789 - Drug Profile 122
DS-107 - Drug Profile 123
NVN-1000 - Drug Profile 124
benzoyl peroxide - Drug Profile 125
MUS-92579 - Drug Profile 126
DLX-2323 - Drug Profile 127
MC-5 - Drug Profile 128
Autologous Human Platelet Lysate - Drug Profile 129
ANs-29 - Drug Profile 131
(adapalene + clindamycin hydrochloride) - Drug Profile 132
BBI-3000 - Drug Profile 133
SYN-0051 - Drug Profile 134
SYN-0693 + SYN-0117 - Drug Profile 135
DS-107-F - Drug Profile 136
Urocanic Acid Derivatives - Drug Profile 137
XGP-410 - Drug Profile 138
Drug For Acne - Drug Profile 139
Antimicrobial Peptide For Acne And Skin Cancer - Drug Profile 140
Acne And Related Disorders Therapeutics - Drug Profile Updates 141
Acne And Related Disorders Therapeutics - Dormant Products 151
Acne And Related Disorders - Product Development Milestones 155
Featured News and Press Releases 155
Appendix 162
Methodology 162
Coverage 162
Secondary Research 162
Primary Research 162
Expert Panel Validation 162
Contact Us 163
Disclaimer 163



List of Tables

Number of Products Under Development for Acne And Related Disorders, H1 2013 14
Products under Development for Acne And Related Disorders - Comparative Analysis, H1 2013 15
Number of Products under Development by Companies, H1 2013 17
Number of Products under Development by Companies, H1 2013 (Contd..1) 18
Number of Products under Development by Companies, H1 2013 (Contd..2) 19
Number of Products under Development by Companies, H1 2013 (Contd..3) 20
Number of Products under Investigation by Universities/Institutes, H1 2013 21
Comparative Analysis by Late Stage Development, H1 2013 22
Comparative Analysis by Mid Clinical Stage Development, H1 2013 23
Comparative Analysis by Early Clinical Stage Development, H1 2013 24
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 25
Products under Development by Companies, H1 2013 26
Products under Development by Companies, H1 2013 (Contd..1) 27
Products under Development by Companies, H1 2013 (Contd..2) 28
Products under Development by Companies, H1 2013 (Contd..3) 29
Products under Investigation by Universities/Institutes, H1 2013 30
Boehringer Ingelheim GmbH, H1 2013 31
Photocure ASA, H1 2013 32
Valeant Pharmaceuticals International, H1 2013 33
GlaxoSmithKline plc, H1 2013 34
Galderma S.A., H1 2013 35
Meda AB, H1 2013 36
Merz GmbH and Co. KGaA, H1 2013 37
Toyama Chemical Co. Ltd, H1 2013 38
Paratek Pharmaceuticals, Inc., H1 2013 39
AntiCancer, Inc., H1 2013 40
Helix BioMedix, Inc., H1 2013 41
Cosmo Pharmaceuticals S.p.A, H1 2013 42
XOMA Ltd., H1 2013 43
Quest PharmaTech Inc., H1 2013 44
Phynova Group Ltd, H1 2013 45
Syntopix Group Plc, H1 2013 46
Phosphagenics Limited, H1 2013 47
Foamix Ltd., H1 2013 48
Novabiotics Ltd, H1 2013 49
AndroScience Corporation, H1 2013 50
Hygeia Therapeutics, Inc., H1 2013 51
NovaLead Pharma Pvt. Ltd., H1 2013 52
NanoBio Corporation, H1 2013 53
ELORAC, Inc., H1 2013 54
Laboratorios SALVAT S.A., H1 2013 55
Braintree Laboratories, Inc., H1 2013 56
Maruho Co.,Ltd., H1 2013 57
Lee's Pharmaceutical Holdings Limited, H1 2013 58
Mimetica Pty Ltd., H1 2013 59
Fibrocell Sciences, Inc., H1 2013 60
Ausio Pharmaceuticals, LLC, H1 2013 61
XBiotech USA, Inc., H1 2013 62
FunZyme BioTechnologies S.A., H1 2013 63
Immune Technologies and Medicine, H1 2013 64
Advancell, H1 2013 65
Assessment by Monotherapy Products, H1 2013 66
Assessment by Combination Products, H1 2013 67
Assessment by Stage and Route of Administration, H1 2013 69
Assessment by Stage and Molecule Type, H1 2013 71
Acne And Related Disorders Therapeutics - Drug Profile Updates 145
Acne And Related Disorders Therapeutics - Dormant Products 155
Acne And Related Disorders Therapeutics - Dormant Products (Contd..1) 156
Acne And Related Disorders Therapeutics - Dormant Products (Contd..2) 157
Acne And Related Disorders Therapeutics - Dormant Products (Contd..3) 158



List of Figures

Number of Products under Development for Acne And Related Disorders, H1 2013 14
Products under Development for Acne And Related Disorders - Comparative Analysis, H1 2013 15
Products under Development by Companies, H1 2013 16
Products under Investigation by Universities/Institutes, H1 2013 21
Late Stage Products, H1 2013 22
Mid Clinical Stage Products, H1 2013 23
Early Clinical Stage Products, H1 2013 24
Discovery and Pre-Clinical Stage Products, H1 2013 25
Assessment by Monotherapy Products, H1 2013 66
Assessment by Combination Products, H1 2013 67
Assessment by Route of Administration, H1 2013 68
Assessment by Stage and Route of Administration, H1 2013 69
Assessment by Molecule Type, H1 2013 70
Assessment by Stage and Molecule Type, H1 2013 71

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Radiodermatitis Market: - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Radiodermatitis Market: - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • September 2016
  • by Transparency Market Research

Radiodermatitis, also known as radiation dermatitis, is a significant symptom caused by radiation therapy used in treating cancer as well as exposure to radiation during nuclear disasters. During cance ...

Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global phototherapy equipment market is projected to reach USD 583.4 million by 2021, growing at a CAGR of 4.5% during the forecast period of 2016 to 2021. This market is primarily driven by the huge ...

Eczema - Market Insights, Epidemiology and Market Forecast-2023

Eczema - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Eczema - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.